Had a look back at my notes, FY18 Average Quarterly OPEX was $700k.
So we need around 500% growth on quarterly receivables to shake off our current risk profile, which seems like a lot but is achievable when looking into CCP's addressable market.
FGF have done well floating ACU & CyprotVault tokens, I wonder if they will circle back to CCP and provide more funding.
The waiting game is now in with KoolMax to spread our product across their client base, sadly dicker data have not come through and not much news from other channel partners either. My 'projection' is ~$1M in sales FY19 with cash positive mid-2020.
Very much a high risk spec stock here, though solid management and world class product usually gets thing over the line
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
Had a look back at my notes, FY18 Average Quarterly OPEX was...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.474M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 23495490 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 338053 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 187500 | 0.008 |
4 | 660631 | 0.007 |
2 | 1091666 | 0.006 |
2 | 1266959 | 0.005 |
1 | 150000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 47144 | 1 |
0.010 | 1000000 | 1 |
0.012 | 305828 | 1 |
0.013 | 159960 | 1 |
0.014 | 71499 | 1 |
Last trade - 16.00pm 25/11/2024 (20 minute delay) ? |
Featured News
CT1 (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online